Oral ONC201 in Relapsed/Refractory Multiple Myeloma
NCT02863991
Terminated
This was a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone in adults with relapsed/refractory multiple myeloma. The primary objective of this study was to evaluate the antitumor efficacy of ONC201. Note: This study was completed by predecessor company, Oncoceutics, Inc.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: The Mount Sinai Medical Center, New York, New York +1 locations
Conditions: Multiple Myeloma
Register for Updates
Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema
NCT04411693
Completed
This study is an interventional, prospective randomized study comparing the dexamethasone implant to intravitreal aflibercept. Subjects will have an initial single injection of aflibercept and will be randomized if diabetic macular edema persists. Each subject will be evaluated for 6 months following randomization. Thus, the study duration will be 12 months plus the recruitment period. Subjects will be evaluated every month for safety, efficacy as measured by SDOCT and best corrected visual acu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Retina Consultants of Houston, Houston, Texas
Conditions: Diabetic Macular Edema
Register for Updates
Differential Efficacy of Corticosteroid Solutions for Non-Operative Treatment of Digit Flexor Tenosynovitis
NCT04002037
Terminated
Trigger finger is a common cause of hand pain and dysfunction. Its due to chronic inflammation of the flexor tendon that leads to a pulley system mismatch. Historically it has been managed either conservatively with corticosteroid injections or through a surgical release of the A1 pulley. Several corticosteroids have been used for injection- dexamethasone, methylprednisolone, triamcinolone, betamethasone, paramethasone, etc. The purpose of out study is to determine if a 0.5 cc injection of Triam... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: University of Missouri Health Care, Columbia, Missouri
Conditions: Trigger Finger
Register for Updates
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT04956302
Terminated
This phase I trial studies the possible benefits and side effects of adding panobinostat to a combination of daratumumab, bortezomib and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or has not responded to treatment (refractory). Panobinostat may stop or slow multiple myeloma by blocking the growth of new blood vessels necessary for cancer growth. Giving panobinostat in combination with daratumumab, bortezomib and dexamethasone may work better in treatin... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
NCT02348216
Completed
This study will be separated into 3 distinct phases designated as the Phase 1 study, Phase 2 pivotal study (Cohort 1 and Cohort 2), and Phase 2 safety management study (Cohort 3 and Cohort 4, Cohort 5 and Cohort 6). The primary objectives of this study are: * Phase 1 Study: Evaluate the safety of axicabtagene ciloleucel regimens * Phase 2 Pivotal Study; Evaluate the efficacy of axicabtagene ciloleucel * Phase 2 Safety Management Study: Assess the impact of prophylactic regimens or earlier inte... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +35 locations
Conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
Register for Updates
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT06232707
Withdrawn
The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: Local Institution - 0151, Birmingham, Alabama +169 locations
Conditions: Multiple Myeloma
Register for Updates
A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
NCT04580121
Completed
This open-label, entry-into-human (EIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of RO7283420. Escalating doses of RO7283420 will be administered to participants with Acute Myeloid Leukemia (AML) in order to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: UC Davis Comprehensive Cancer Center, Sacramento, California +22 locations
Conditions: Acute Myeloid Leukemia
Register for Updates
Septorhinoplasty Post-operative Pain Control With SPG Nerve Block
NCT05667324
Recruiting
Maxillary nerve blocks have been shown to significantly reduce post-operative pain and analgesic intake during the 24-hour period following sinus surgery. This randomized, double-blinded, placebo-controlled study will investigate blocks of the pterygopalatine fossa using a suprazygomatic approach during septorhinoplasty surgery. It is the investigator's hypothesis that this technique will result in decreased post-operative pain and opioid use, and the morbidity associated with it.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/29/2024
Locations: UF Health of University of Florida, Gainesville, Florida
Conditions: Deviated Nasal Septum
Register for Updates
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
NCT01919086
Completed
The purpose of this study is to see if researchers could get the same good results with less toxicity by using this new approach. We already know that the three drugs bortezomib, lenalidomide, and dexamethasone given together at the same time are effective. Most physicians therefore treat patients with multiple myeloma with the 3 drug combination. However, the researchers also know that the three drugs given together result in more side effects than when only 2 drugs (bortezomib and dexamethaso... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut +6 locations
Conditions: Multiple Myeloma (MM)
Register for Updates
Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block
NCT04559425
Recruiting
Few studies are specifically designed to address health concerns that are already relevant during pregnancy. The consequence is a lack of evidence on best clinical practice. This includes mothers and their babies when pregnancy is complicated by an abnormally slow heart rate due to maternal antibody-mediated heart disease in the unborn baby (fetus). Since the late seventies, it has been possible to detect and monitor fetal disease by ultrasound images and to treat selected conditions with pharma... Read More
Gender:
FEMALE
Ages:
Between 16 years and 50 years
Trial Updated:
05/21/2024
Locations: Phoenix Children's Hospital, Phoenix, Arizona +26 locations
Conditions: Heart Block Complete, Heart Block Second Degree
Register for Updates
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
NCT04474223
Recruiting
Fetal complete (i.e., third degree, 3°) atrioventricular block (AVB), identified in the 2nd trimester of pregnancy in an otherwise normally developing heart, is almost universally associated with maternal anti-Ro autoantibodies and results in death in a fifth of cases. To date treatment of 3° AVB has been ineffective in restoring normal rhythm (NR) which may be because current surveillance is limited to once- weekly fetal echocardiograms. It is hypothesized that there may be a vital transition p... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: Phoenix Children's Hospital/Dignity Health, Phoenix, Arizona +23 locations
Conditions: AVB - Atrioventricular Block, Fetal AVB
Register for Updates
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT02101944
Completed
This phase I trial studies the side effects and best dose of wild-type reovirus when combined with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back following treatment (relapsed) or does not respond to treatment (refractory). Chemotherapy drugs, such as dexamethasone and carfilzomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. A virus called w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia +2 locations
Conditions: Anemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates